Toward Novel Vaccines Against Tuberculosis: Current Hopes and Obstacles

Thaiss, Christoph A.; Kaufmann, Stefan H. E.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Toward Novel Vaccines Against Tuberculosis: Current Hopes and Obstacles

MPS-Authors

/persons/resource/persons81969

Kaufmann, Stefan H. E.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Yale_J_Biol_Med_2010_83_209.pdf
(Publisher version), 192KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Thaiss, C. A., & Kaufmann, S. H. E. (2010). Toward Novel Vaccines Against Tuberculosis: Current Hopes and Obstacles. Yale Journal of Biology and Medicine, 83(4), 209-215.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-BF6B-1

Abstract

Approximately 2 million people die of tuberculosis (TB) each year. The current vaccine, Bacille Calmette-Guérin (BCG), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of TB worldwide. New insights into the cellular and molecular mechanisms that underlie the interactions between Mycobacterium tuberculosis and its host have been exploited to develop novel vaccine candidates that recently have entered clinical trials. This review provides a brief overview of different approaches toward a new vaccination strategy and summarizes major challenges for the next decade.